Boehringer Ingelheim strikes $7.4 billion deal with Sino Biopharma for preclinical ADC and TCE programs

Boehringer Ingelheim announced a major licensing agreement with China's Sino Biopharmaceutical, paying $358 million upfront for a six‑program option covering preclinical antibody‑drug conjugates and T‑cell engagers.

Five of the programs come from Sino’s LaNova Medicines unit and one from its Beijing Tide Pharmaceutical subsidiary. Sino will manage early development and aim for clinical milestones that trigger additional payments.

Boehringer will have the option to purchase worldwide rights to two of the candidates and the ex‑China rights to the remaining four, with total potential payments up to $7 billion based on exercised options and milestones.

The deal reflects Boehringer’s stated focus on ADC and TCE modalities, reinforcing its strategy to expand its pipeline through external innovation.